MedX Health and Sanitas Spain Announce a Large-Scale Skin Cancer Screening Initiative in Spain Using MedX’s DermSecure™ Technology
June 17, 2019 (Source) – MedX Health Corp. (“MedX”) (TSX-V:MDX) announces that it has partnered with SANITAS, a specialist in healthcare and well-being services in Spain, to conduct a skin cancer screening initiative. According to recent studies, Spain, with its warm and sunny climate has experienced a 50% increase in skin cancer rates over the last decade. It is the most common form of cancer in women between the age of 25 and 29, followed by breast cancer, and the most common in men between the age of 30 and 35, ahead of lung and colon cancer.
MedX, with its Spanish distributor (OncoTech), has partnered with SANITAS, who will target twelve of SANITAS’s multi-national company customers, with up to 3,000 patient scans to be taken using MedX’s DermSecure™, to assess the benefits of such an initiative to SANITAS, its clients and the Spanish healthcare system. Upon completion, SANITAS will consider a significant expansion of this program. Dr. Miguel Marine Blanco, Director of Strategic Alliances for SANITAS commented, “With the increase in skin cancer rates in Spain we felt being able to offer our members skin cancer screening with the best screening technology available would be well received by our members.”
Sanitas offers its clients products and services adapted to people’s real needs at each stage of their lives through an integral healthcare model that includes: medical insurance, hospitals and multi-speciality centres, well-being centres, dental clinics, other health services and services for the care of the elderly. Sanitas forms part of Bupa, a leading international healthcare company, which serves over 15.7 million insurance policy holders, 15 million patients and 23,000 elderly people.
Mr. Frank Melendez, OncoTech’s President stated, “It is an honour to work with SANITAS and their multi-national customers. They truly wish to deliver the best possible care to their members which speaks to their success. We are looking forward to the results of this pilot and to further expand this program in the future.”
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com
Get our daily investorintel update
Sanitas is a specialist in healthcare and well-being services in Spain. It offers its clients products and services adapted to people’s real needs at each stage of their lives through an integral healthcare model that includes: medical insurance, hospitals and multi-speciality centres, well-being centres, dental clinics, other health services and services for the care of the elderly.
It has 10,859 employees; it has a medical team made up of over 40,000 specialists and 1,200 associated medical centres, in addition to its own service, formed by 4 hospitals, 20 multi-speciality medical centres, 16 well-being centres, 180 dental clinics, 47 homes for the elderly, 17 of them with day centre services and 5 independent day centres.
Sanitas forms part of Bupa, a leading international healthcare company, which serves over 15.7 million insurance policy holders, 15 million patients and 23,000 elderly people.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
InvestorIntel is a trusted source of reliable information at the forefront of emerging markets that brings investment opportunities to discerning investors.